Abstract
In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous stem cell transplantation. Here we present recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients. These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Smith A, Wisloff F, Samson D . Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132: 410–451.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ et al. SEER Cancer Statistics Review, 1975–2005. National Cancer Institute: Bethesda, MD, 2008.
Durie BGM, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–398.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009, doi:10.1038/leu.2009.89.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215–224.
Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J . Initial versus deferred melphalan-prednisone therapy for asymptomatic myltiple myeloma stage I—a randomized study. Eur J Haematol 1993; 50: 95–102.
Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of disease: a multicentre randomized study. Br J Cancer 2000; 82: 1254–1260.
Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933–1937.
Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008; 22: 1767–1772.
Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.
Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis in myeloma. Blood 2005; 106: 3553–3558.
Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.
Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR . Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902.
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT . Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491.
Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2008; 113: 3435–3442.
Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris Ch et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995.
Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi. J Clin Oncol 2008; 26 (abstract [8504]).
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BR et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood 2007; 110 (abstract [77]).
Zonder JA, Crowley JJ, Bolejack V, Hussein MA, Moore DF, Whittenberger M et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. J Clin Oncol 2008; 26 (abstract [8521]).
Gulbrandsen N, Waage A, Gimsing P, Turesson I, Juliusson G, Ablidgaard N et al. A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 2008; 93 (abstract [0209]).
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831.
Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008a; 112: 3107–3114.
Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pergourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209–1218.
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyenet C et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007; 110 (11 part 1) Abstract 75.
Wijermans P, Schaafsma M, van Norden Y, Ammerlaan R, Wittebol S, Sinnige H et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: Final analysis of the Dutch cooperative group HOVON 49 study. Blood 2008; 112 (abstract [649]).
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.
Mateos MV, Oriol A, Martinez J, Cibeira MT, de Paz R, Terol MJ et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade: An alkylating or an immunomodulator agent? Blood 2008; 112 (abstract [651]).
Palumbo A, Bringhen S, Rossi D, Magarotto V, Di Raimondo F, Ria R et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008b; 112 (abstract [652]).
Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 2007a; 25: 4459–4465.
Palumbo A, Falco P, Gay F, Corradini P, Crippa C, Di Raimondo F et al. Oral melphalan, prednisone, and lenalidomide for newly diagnosed multiple myeloma patients: kinetics of neutropenia/thrombocytopenia and time to event results. Blood 2008c; 112 (abstract [2768]).
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.
Palumbo A, Falco P, Gay F, Montefusco V, Crippa C, Patriarca F et al. Bortezomib-doxorubicin-dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood 2008d; 112 (abstract [159]).
Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805–1810.
Mihelic R, Kaufman JL, Lonial S . Maintenance therapy in multiple myeloma. Leukemia 2007; 21: 1150–1157.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403.
Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009; 144: 169–175.
Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006; 91: 133–136.
Hussein MA, Baz R, Srkalovic G, Agrawal N, Supplah R, Hsi E et al. Phase 2 study of pegulated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889–895.
Kyriakou C, Thomson K, D’Sa S, Flory A, Hanslip J, Goldstone AH et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129: 763–770.
Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117.
García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863.
Kropff M, Lang N, Bisping G, Domine N, Innig G, Hentrich M et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616.
Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17: 1766–1771.
Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O et al. Lenalidomide (Revlimid(R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myeloma. Blood 2009; 113: 4137–4143.
Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137: 268–269.
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ . The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica 2007; 92: 1149–1150.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138: 330–337.
Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26: 4777–4783.
Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008e; 19: 1160–1165.
Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22: 1419–1427.
Richardson PG, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood 2006; 108 (abstract [405]).
Richardson P, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008; 112 (abstract [1742]).
Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexameethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247–2256.
Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A . The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008; 141: 814–819.
Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112: 4445–4451.
Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 2007a; 25: 4459–4465.
Sezer O . Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009; 14: 276–283.
Mill WB, Griffith R . The role of radiation therapy in the management of plasma cell tumours. Cancer 1980; 45: 647–652.
Leigh BR, Kurtts TA, Mack CF, Matzner MB, Shimm DS . Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993; 25: 801–804.
Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E et al. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008; 22: 1479–1484.
Berenson JR, Tillman JB, Hussein MA, Pflugmacher R, Jarzem P, Elmoufti S et al. A phase III trial of kyphoplasty versus nonsurgical care for cancer patients with vertebral fractures. Clin Lymphoma Myeloma 2009, Abstract 204: 28.
World Health Organization (1996) Cancer pain relief, 2nd edn. WHO Technical Report Series, No. 804: Geneva, Switzerland.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008f; 22: 414–423.
Argyriou AA, Iconomou G, Kalofonos HP . Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593–1599.
Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.
Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767–2772.
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix A-1
Appendix A-1
International Myeloma Working Group:
Rafat Abonour, Indiana University School of Medicine, Indianapolis, Indiana, USA
Ray Alexanian, MD Anderson, Houston, Texas, USA
Kenneth Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Michael Attal, Purpan Hospital, Toulouse, France
Herve Avet-Loiseau, Institute de Biologie, Nantes, France
Ashraf Badros, University of Maryland, Baltimore, Maryland, USA
Leif Bergsagel, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
Joan Bladé, Hospital Clinica, Barcelona, Spain
Bart Barlogie, M.I.R.T. UAMS Little Rock, Arkanas, USA
Regis Batille, Institute de Biologie, Nantes, France
Meral Beksac, Ankara University, Ankara, Turkey
Andrew Belch, Cross Cancer Institute, Alberta, Canada
Bill Bensinger, Fred Hutchinson Cancer Center, Seattle, Washington, USA
Mario Boccadoro, University of Torino, Torino, Italy
Michele Cavo, Universita di Bologna, Bologna, Italy
Wen Ming Chen, MM Research Center of Beijing, Beijing, China
Tony Child, Leeds General Hospital, Leeds, United Kingdom
James Chim, Department of Medicine, Queen Mary Hospital, Hong Kong
Ray Comenzo, Tufts Medical Center, Boston, Massachusetts, USA
John Crowley, Cancer Research and Biostatistics, Seattle, Washington, USA
William Dalton, H Lee Moffitt, Tampa, Florida, USA
Faith Davies, Royal Marsden Hospital, London, England
Cármino de Souza, Univeridade de Campinas, Caminas, Brazil
Michel Delforge, University Hospital Gasthuisberg, Leuven, Belgium
Meletios Dimopoulos, Alexandra Hospital, Athens, Greece
Angela Dispenzieri, Mayo Clinic, Rochester, Minnesota, USA
Brian GM Durie, Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, USA
Hermann Einsele, Universitätsklinik Würzburg, Würzburg, Germany
Theirry Facon, Centre Hospitalier Regional Universitaire de Lille, Lille, France
Dorotea Fantl, Socieded Argentinade Hematolgia, Buenos Aires, Argentina
Jean-Paul Fermand, Hopitaux de Paris, Paris, France
Rafael Fonseca, Mayo Clinic Arizona, Scottsdale, Arizona, USA
Gosta Gahrton, Karolinska Institute for Medicine, Huddinge, Sweden
Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA
John Gibson, Royal Prince Alfred Hospital, Sydney, Australia
Sergio Giralt, MD Anderson Cancer Center, Houston, Texas, USA
Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany
Philip Greipp, Mayo Clinic, Rochester, Minnesota, USA
Roman Hajek, Brno University, Brno, Czech Republic
Izhar Hardan, Tel Aviv University, Tel Aviv, Israel
Jean-Luc Harousseau, Institute de Biologie, Nantes, France
Hiroyuki Hata, Kumamoto University Hospital, Kumamoto, Japan
Yutaka Hattori, Keio University School of Medicine, Tokyo, Japan
Joy Ho, Royal Prince Alfred Hospital, Sydney, Australia
Vania Hungria, Clinica San Germano, Sao Paolo, Brazil
Shinsuke Ida, Nagoya City University Medical School, Nagoya, Japan
Peter Jacobs, Constantiaberg Medi-Clinic, Plumstead, South Africa
Sundar Jagannath, St Vincent's Comprehensive Cancer Center, New York, New York, USA
Hou Jian, Shanghai Chang Zheng Hospital, Shanghai, China
Douglas Joshua, Royal Prince Alfred Hospital, Sydney, Australia
Michio Kawano, Yamaguchi University, Ube, Japan
Nicolaus Kröger, University Hospital Hamburg, Hamburg, Germany
Shaji Kumar, Department of Hematology, Mayo Clinic, Minnesota, USA
Robert Kyle, Department of Laboratory Med. and Pathology, Mayo Clinic, Minnesota, USA
Juan Lahuerta, Grupo Espanol di Mieloma, Hospital Universitario, Madrid, Spain
Ola Landgren, National Cancer Institute, N.I.H. Bethesda, Maryland, USA
Jae Hoon Lee, Gachon University Gil Hospital, Incheon, Korea
Xavier LeLeu, Hospital Huriez, CHRU Lille, France
Suzanne Lentzsch, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Henk Lokhorst, University Medical Center Utrecht, Utrecht, The Netherlands
Sagar Lonial, Emory University Medical School, Atlanta, Georgia, USA
Heinz Ludwig, Wilhelminenspital Der Stat Wien, Vienna, Austria
Angelo Maiolino, Rua fonte da Saudade, Rio de Janeiro, Brazil
Maria Mateos, University of Salamanca, Salamanca, Spain
Jayesh Mehta, Northwestern University, Chicago, Illinois, USA
GianPaolo Merlini, University of Pavia, Pavia, Italy
Joseph Mikhael, Mayo Clinic Arizona, Scottsdale, Arizona, USA
Philippe Moreau, University Hospital, Nantes, France
Gareth Morgan, Royal Marsden Hospital, London, England
Nikhil Munshi, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Ruben Niesvizky, Weill Medical College of Cornell University, New York, New York, USA
Yana Novis, Hospital SírioLibanês, Bela Vista, Brazil
Amara Nouel, Hospital Rutz y Paez, Bolivar, Venezuela
Robert Orlowski, MD Anderson Cancer Center, Houston, Texas, USA
Antonio Palumbo, Cathedra Ematologia, Torino, Italy
Santiago Pavlovsky, Fundaleu, Buenos Aires, Argentina
Linda Pilarski, University of Alberta, Alberta, Canada
Raymond Powles, Leukaemia and Myeloma, Wimbledon, England
S Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota, USA
Donna Reece, Princess Margaret Hospital, Toronto, Canada
Tony Reiman, Cross Cancer Institute, Alberta, Canada
Paul Richardson, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Angelina Rodriquez Morales, Bonco Metro Politano de Sangre, Caracas, Venezuela
Orhan Sezer, Department of Hem/Onc, Universitatsklinikum Charite, Berlin, Germany
John Shaughnessy, M.I.R.T. UAMS, Little Rock, Arkansas, USA
Kazuyuki Shimizu, Nagoya City Midori General Hospital, Nagoya, Japan
David Siegel, Hackensack, Cancer Center, Hackensack, New Jersey, USA
Jesus San Miguel, University of Salamanca, Salamanca, Spain
Chaim Shustik, McGill University, Montreal, Canada
Seema Singhal, Northwestern University, Chicago, Illinois, USA
Pieter Sonneveld, Erasmus MC, Rotterdam, The Netherlands
Andrew Spencer, The Alfred Hospital, Melbourne, Australia
Edward Stadtmauer, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Keith Stewart, Mayo Clinic Arizona, Scottsdale, Arizona, USA
Evangelos Terpos, University of Athens School of Medicine, Athens, Greece
Patrizia Tosi, Italian Cooperative Group, Istituto di Ematologia Seragnoli, Bologna, Italy
Guido Tricot, Huntsman Cancer Institute, Salt Lake City, Utah, USA
Ingemar Turesson, Department of Hematology, Malmo University, Malmo, Sweden
Brian Van Ness, University of Minnesota, Minneapolis, Minnesota, USA
Ivan Van Riet, Brussels Vrija University, Brussels, Belgium
Robert Vescio, Cedars-Sinai Cancer Center, Los Angeles, California, USA
David Vesole, Loyola University Chicago, Illinois, USA
Anders Waage, University Hospital, Trondheim, Norway
Michael Wang, M.D. Anderson, Houston, Texas, USA
Donna Weber, MD Anderson, Houston, Texas, USA
Jan Westin, Sahlgrenska University Hospital, Gothenburg, Sweden
Keith Wheatley, University of Birmingham, Birmingham, United Kingdom
Dina B Yehuda, Department of Hematology, Hadassah University Hospital, Hadassah, Israel
Jeffrey Zonder, SWOG, Department of Hem/Onc., Karmanos Cancer Institute, Michigan, USA
Rights and permissions
About this article
Cite this article
Palumbo, A., Sezer, O., Kyle, R. et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23, 1716–1730 (2009). https://doi.org/10.1038/leu.2009.122
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.122
Keywords
This article is cited by
-
Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents
Bone Marrow Transplantation (2019)
-
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
Scientific Reports (2016)
-
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
Bone Marrow Transplantation (2015)
-
Reconstruction of multiple myeloma lesions around the pelvis and acetabulum
European Journal of Orthopaedic Surgery & Traumatology (2015)
-
Treatment-related symptom management in patients with multiple myeloma: a review
Supportive Care in Cancer (2015)